

January 21, 2026

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd. Exchange
Plaza, 5th floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III thereto, we wish to inform that the Executive Business Committee ("EBC") of the Company, under its delegated authority, has approved the transfer of the shares held by the Company in its foreign subsidiary PellucidCare Health Innovations Pte Ltd (formerly known as FMV Healthcare Pte Ltd), Singapore to FlynnCare Health Innovations Private Limited, a wholly owned subsidiary of Fischer Medical Ventures Limited as part of an internal group reorganisation.

The aforesaid transfer is being undertaken for administrative and operational efficiency. Post completion of the transaction, there shall be no change in the ultimate ownership, control, management or economic interest of the Company in the said foreign subsidiary.

The transaction is between the Holding Company and its wholly owned subsidiary and hence does not have any material impact on the consolidated financials of the Company. This disclosure is being made in compliance with the applicable provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015.

This is for the information of the exchange and the members.

Thanking you,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

ARAVINDKUMAR V

COMPANY SECRETARY AND COMPLIANCE OFFICER

